BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 36643372)

  • 1. Current status of liver transplantation for non-B non-C liver cirrhosis and hepatocellular carcinoma.
    Nishio T; Ito T; Hata K; Taura K; Hatano E
    Ann Gastroenterol Surg; 2023 Jan; 7(1):42-52. PubMed ID: 36643372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic Steatohepatitis Becomes the Leading Indication for Liver Transplant Registrants Among US Adults Born Between 1945 and 1965.
    Shirazi F; Wang J; Wong RJ
    J Clin Exp Hepatol; 2020; 10(1):30-36. PubMed ID: 32025164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis.
    Castelló B; Aguilera V; Blázquez MT; Rubín Á; García M; Vinaixa C; Benlloch S; SanJuan F; Montalva E; López R; Berenguer M
    Ann Hepatol; 2019; 18(6):855-861. PubMed ID: 31543468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.
    Younossi Z; Stepanova M; Ong JP; Jacobson IM; Bugianesi E; Duseja A; Eguchi Y; Wong VW; Negro F; Yilmaz Y; Romero-Gomez M; George J; Ahmed A; Wong R; Younossi I; Ziayee M; Afendy A;
    Clin Gastroenterol Hepatol; 2019 Mar; 17(4):748-755.e3. PubMed ID: 29908364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?
    Mikolasevic I; Filipec-Kanizaj T; Mijic M; Jakopcic I; Milic S; Hrstic I; Sobocan N; Stimac D; Burra P
    World J Gastroenterol; 2018 Apr; 24(14):1491-1506. PubMed ID: 29662288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis.
    Villeret F; Dharancy S; Erard D; Abergel A; Barbier L; Besch C; Boillot O; Boudjema K; Coilly A; Conti F; Corpechot C; Duvoux C; Faitot F; Faure S; Francoz C; Giostra E; Gugenheim J; Hardwigsen J; Hilleret MN; Hiriart JB; Houssel-Debry P; Kamar N; Lassailly G; Latournerie M; Pageaux GP; Samuel D; Vanlemmens C; Saliba F; Dumortier J
    JHEP Rep; 2023 Mar; 5(3):100668. PubMed ID: 36852108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic Fatty Liver Disease: Epidemiology, Liver Transplantation Trends and Outcomes, and Risk of Recurrent Disease in the Graft.
    Liu A; Galoosian A; Kaswala D; Li AA; Gadiparthi C; Cholankeril G; Kim D; Ahmed A
    J Clin Transl Hepatol; 2018 Dec; 6(4):420-424. PubMed ID: 30637220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016.
    Golabi P; Bush H; Stepanova M; Locklear CT; Jacobson IM; Mishra A; Trimble G; Erario M; Venkatesan C; Younossi I; Goodman Z; Younossi ZM
    Medicine (Baltimore); 2018 Aug; 97(31):e11518. PubMed ID: 30075518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rising Rates of Hepatocellular Carcinoma Leading to Liver Transplantation in Baby Boomer Generation with Chronic Hepatitis C, Alcohol Liver Disease, and Nonalcoholic Steatohepatitis-Related Liver Disease.
    Cholankeril G; Yoo ER; Perumpail RB; Liu A; Sandhu JS; Nair S; Hu M; Ahmed A
    Diseases; 2017 Sep; 5(4):. PubMed ID: 28954412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease.
    Majumdar A; Tsochatzis EA
    Metabolism; 2020 Oct; 111S():154291. PubMed ID: 32531295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and Risks for Nonalcoholic Fatty Liver Disease and Steatohepatitis Post-liver Transplant: Systematic Review and Meta-analysis.
    Saeed N; Glass L; Sharma P; Shannon C; Sonnenday CJ; Tincopa MA
    Transplantation; 2019 Nov; 103(11):e345-e354. PubMed ID: 31415032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates .
    Samji NS; Heda R; Satapathy SK
    Transl Gastroenterol Hepatol; 2020; 5():10. PubMed ID: 32190778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis.
    Galvin Z; Rajakumar R; Chen E; Adeyi O; Selzner M; Grant D; Sapisochin G; Greig P; Cattral M; McGilvray I; Ghanekar A; Selzner N; Lilly L; Patel K; Bhat M
    Liver Transpl; 2019 Jan; 25(1):56-67. PubMed ID: 30609189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes and Hepatocellular Carcinoma: Incidence Trends and Impact of Liver Disease Etiology.
    Doycheva I; Zhang T; Amjad W; Thuluvath PJ
    J Clin Exp Hepatol; 2020; 10(4):296-303. PubMed ID: 32655232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
    Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
    Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High incidence of hepatocellular carcinoma and postoperative complications in patients with nonalcoholic steatohepatitis as a primary indication for deceased liver transplantation.
    Kern B; Feurstein B; Fritz J; Fabritius C; Sucher R; Graziadei I; Bale R; Tilg H; Zoller H; Newsome P; Eschertzhuber S; Margreiter R; Öfner D; Schneeberger S
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):205-210. PubMed ID: 30320609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma.
    Lewin SM; Mehta N; Kelley RK; Roberts JP; Yao FY; Brandman D
    Liver Transpl; 2017 Aug; 23(8):1015-1022. PubMed ID: 28340509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.